Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 30  |  Issue : 3  |  Page : 887-891

Plasminogen activator inhibitor-1 SERPINE1 4G/5G polymorphism in hepatocellular carcinoma patients


Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebein El-Kom, Egypt

Correspondence Address:
Sara A. M. Hegazy
Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebein El-Kom, Menoufia Governorate, 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.218258

Rights and Permissions

Objective The aim of this study was to investigate the distribution of genotypes and the frequency alleles of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in patients with hepatocellular carcinoma (HCC). Background PAI-1 4G/5G polymorphism involves a guanosine insertion/deletion in the promoter region of SERPINE1 gene at the –675 bp position. Patients and methods This study was conducted on 49 HCC patients (39 male and 10 female). Their ages ranged between 44 and 84 years. They were selected from the inpatient and outpatient clinics of Shibin El-Kom Fever Hospital. Patients were genotyped for PAI-1 4G/5G polymorphism using PCR. Results In HCC patients, there were no statistically significant differences when comparing carriers of the three genotypes (5G/5G, 4G/5G, and 4G/4G) as regards sex, Child score, total bilirubin, direct bilirubin, albumin, serum glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyltranspeptidase, international normalized ratio, prothrombin, and α-fetoprotein (P = 0.81, 0.76, 0.46, 0.054, 0.99, 0.92, 0.22, 0.58, 0.49, 0.42, 0.54, and 0.85, respectively). On comparing the three genotypes (5G/5G, 4G/5G, and 4G/4G) among HCC patients as regards serum glutamic oxaloacetic transaminase, there was a statistically significant difference among them (P = 0.02). On comparing carriers of the three genotypes (5G/5G, 4G/5G, and 4G/4G) as regards different tumor characters (tumor size, tumor number, tumor side, and Barcelona Clinic Liver Cancer staging system), there were no significant differences among them (P = 0.16, 0.59, 0.42, and 0.14, respectively). Rate of thrombosis in the HCC group was 62.5% in 4G/5G genotype versus 41.2 and 12.5% in 5G/5G and 4G/5G genotype, respectively; there was a statistically significant difference (P = 0.04). Conclusion It could be concluded that PAI-1 4G/5G polymorphism was not associated with HCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed577    
    Printed8    
    Emailed0    
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal